Summary:
- This article reports on the results of a Phase 3 clinical trial for Dupixent (dupilumab), a drug used to treat chronic spontaneous urticaria (CSU), a condition characterized by recurring hives and severe itch.
- The trial found that Dupixent significantly improved itch and hives in patients with CSU compared to placebo, with a majority of patients achieving a clinically meaningful reduction in itch and hives.
- The positive results from this trial support the potential of Dupixent as a new treatment option for patients with CSU, a condition that can significantly impact quality of life.